Tomaralimab clinical trials
Also written OPN-305.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses tomaralimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- OPN-305
- 3
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Opsona Therapeutics Ltd. (3)
Studies
Open first, then newest update. How each study uses tomaralimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic SyndromeCompletedPhase 1/2Opsona Therapeutics Ltd.NCT02363491Written as OPN-305
- Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic SyndromeCompletedPhase 1/2Opsona Therapeutics Ltd.NCT03337451Written as OPN-305
- Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft FunctionCompletedPhase 2Opsona Therapeutics Ltd.NCT01794663Written as OPN-305
Codes
What other systems call tomaralimab · ClinicalTrials.gg INT006397
- MeSH (NLM) C585159tomaralimabOne source NLM
- UNII (FDA) P45C2W27DUTOMARALIMABConfirmed FDA, NLM
- NCI Thesaurus C120554TomaralimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585159 | tomaralimab | One source NLM |
| UNII (FDA) | P45C2W27DU | TOMARALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C120554 | Tomaralimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.